Novartis AG Capital Expenditures (CapEx) Growth & History (NVS)

Novartis AG's capital expenditures (capex) was $1.55B for fiscal 2025.

View full Novartis AG company overview

Novartis AG annual capital expenditures (capex) history

Novartis AG annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20252025-12-31$1.55B$182.0M+13.32%
20242024-12-31$1.37B$306.0M+28.87%
20232023-12-31$1.06B$144.0M+15.72%
20222022-12-31$916.0M−$150.0M−14.07%
20212021-12-31$1.07B−$209.0M−16.39%
20202020-12-31$1.27B−$104.0M−7.54%
20192019-12-31$1.38B$125.0M+9.97%
20182018-12-31$1.25B−$71.0M−5.36%
20172017-12-31$1.32B−$537.0M−28.84%
20162016-12-31$1.86B

Novartis AG capital expenditures (capex) trends

Over the last five fiscal years, Novartis AG's capital expenditures (capex) increased from $1.27B to $1.55B, a change of $273.0M. The latest reported quarter, Q2 2026, shows $758.0M.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Novartis AG source filings ↗

Community posts